The QualityStocks Daily Wednesday, June 12th, 2019

Today's Top 3 Investment Newsletters

Schaeffer's (INSY) +139.44%

AwesomeStocks (CLCI) +36.36%

Penny Stock Titans (DGLF) +34.76%

The QualityStocks Daily Stock List

Texas Mineral Resources Corp. (TMRC)

All Penny Stocks, Marketwired, Street Insider, TipRanks, Marketbeat, OilandGas360, StockInvest, InvestorsHub, Stockhouse, InvestorIntel, GlobeNewswire, and Investing News reported beforehand on Texas Mineral Resources Corp. (TMRC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An exploration company, Texas Mineral Resources Corp. targets the heavy rare earths and an array of other high-value elements and industrial minerals. Its focus is exploring and, if warranted, developing its Round Top heavy rare earth and industrial minerals project (950 acres) in Hudspeth County, Texas. The Company previously went by the name Texas Rare Earth Resources Corp. It changed its name to Texas Mineral Resources Corp. in March of 2016. Incorporated in 1970, Texas Mineral Resources is based in Sierra Blanca, Texas.

The Company has established an American Mineral Reclamation subsidiary to seek out and develop lower cost projects involving metals and mineral recovery and reclamation from coal by-products, industrial wastewater, acid mine drainage and scrap metal processing. American Mineral Reclamation, along with industrial partners, is evaluating projects whose objective is the reclamation of high-value elements and industrial minerals from liquid and solid waste material.

Round Top is one of four principal rhyolite bodies, an igneous volcanic rock, making up the group of mountains known as The Sierra Blanca. Regarding the Round Top Project and PEA, the PEA has been completed based on the measured, indicated and inferred Resource Estimate Technical Report filed on December 20, 2013 by Texas Mineral Resources.

The PEA and resource estimate was prepared by Gustavson Associates of Lakewood, Colorado. The resource incorporated into the present mine plan totals 525.4mm kg of rare earth oxide (REO), with an average grade of 634 ppm total rare earth oxides (TREO). Of the TREO, roughly 72 percent consist of heavy rare earth oxides plus Yttrium (Y). Furthermore, Texas Mineral Resources plans on developing alternative sources of strategic minerals via the processing of coal waste and other related materials.

Recently, Texas Mineral Resources announced that a consortium assembled by the Company successfully demonstrated the ability to produce manifold high-purity and separated rare earth minerals from Pennsylvania coal mining waste material. Minerals were purified to a 99.0 percent level, made available for Meeting participant inspection, and included scandium (Sc), dysprosium (Dy), neodymium (Nd), cerium (Ce) and lanthanum (La). Phase One results were reported at the Department of Energy’s 2019 Annual Project Review Meeting for Crosscutting Research, Rare Earth Elements, Gasification Systems and Transformative Power Generation on April 9, 2019 in Pittsburgh, Pennsylvania.

Last week, Texas Mineral Resources, together with its joint venture (JV) partner, USA Rare Earth, LLC, announced plans to release an updated and expanded PEA next month. The expanded 2019 PEA will include an updated resource estimate, adding Lithium, Hafnium, Beryllium, Scandium and Gallium oxides, and also industrial minerals including the sulfates of Aluminum, Iron, Magnesium, Potassium and Sodium. Eight of these additional minerals are on the U.S. Government “Critical Minerals List”, finalized in February of 2018. Moreover, there will be an expansion of the ion exchange processing techniques to be used at Round Top and updated current market mineral pricing will be incorporated into the economic model.

Texas Mineral Resources Corp. (TMRC), closed Wednesday’s trading session at $0.4299, down 14.02%, on 1,688,955 volume with 528 trades. The average volume for the last 3 months is 154,735 and the stock's 52-week low/high is $0.101/$0.515.

chart

ProtoKinetix, Incorporated (PKTX)

Investor Village, ResearchPool, OTC PR Group, Stockwatch, Trading View, 4-Traders, Wallet Investor, and Allstocks reported earlier on ProtoKinetix, Incorporated (PKTX), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A molecular biotechnology company, ProtoKinetix, Incorporated provides medical researchers with a platform for enhancing cell survival and health, in vitro and in vivo. The Company has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance engraftment and protection of transplanted cells, organs, tissues and organs used in regenerative medicine. ProtoKinetix is based in Marietta, Ohio.

At the core of the Company’s technology is its patented anti-aging glycopeptide AAGP™. This small molecule (580 Daltons) displays abilities in resolving challenges facing medical researchers in areas such as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress. Due to its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. In addition, it can function without toxic side effects common in treatments involving larger and less stable compounds. AAGP™ is manufactured at facilities in North America, Europe, and Asia for shipment around the world.

ProtoKinetix is building value via the independent research of laboratories, university and private, into applications for its AAGP™ molecule. Regarding health solutions, there are two chief categories that AAGP™ applications would be divided into. One is regenerative Medicine issues. This includes harvesting, processing, storage and transplanting cells, tissues and organs. The other is treatments for chronic inflammatory conditions and diseases caused by stress factors. This includes UV radiation, oxidation, and cryopreservation and hydrogen cyanide.

Because of the results attained over the last four years of testing, the University of Alberta has started Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed worldwide to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. ProtoKinetix is also studying the potential impact on a number of cancer therapies.

Last month, ProtoKinetix announced that it secured a partnership agreement with IMPART investigator team Canada at Dalhousie University. It has now started studies to reveal the benefits of PKX-001 (AAGP®) in cardiac metabolism. The studies will determine the efficacy of PKX-001 as a cardioprotectant and will be led by Diabetes Canada Scholar, Dr. Thomas Pulinilkunnil.

Last week, ProtoKinetix announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes. All six patients were recruited and treated under this protocol. All primary safety goals were achieved at the midpoint in all study participants. As such, the protocol will now be amended to increase the number of participants in the trial with additional secondary goals added. This includes dose escalation to establish optimization criteria for efficacy testing.

ProtoKinetix, Incorporated (PKTX), closed Wednesday’s trading session at $0.199, down 23.43%, on 994,680 volume with 134 trades. The average volume for the last 3 months is 204,963 and the stock's 52-week low/high is $0.05/$0.319.

chart

Australis Capital, Inc. (AUSAF)

All Penny Stocks, OTC Markets, CannabisMarketCap, The Green Fund, TheCannalysts, Investorx, Micro Small Cap, Pot Stock News, Insider Financial, Proactive Investors, Stockhouse, and New Cannabis Ventures reported previously on Australis Capital, Inc. (AUSAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A spin-out of Aurora Cannabis (NYSE: ACB TSX: ACB) in September of 2018, Australis Capital, Inc. identifies and invests in the cannabis industry mainly in the U.S. Investments may include, but are not limited to, equity, debt or other securities of public and private companies, financings in exchange for royalties or other distribution streams, and control stake acquisitions. Australis Capital lists on the OTCQB. The Company is based in Las Vegas, Nevada.

Australis adheres to strict investment criteria. The Company focuses on significant near and mid-term high-quality opportunities with strong return potentials. This is while maintaining an unwavering commitment to governance and community.

Australis Capital solely concentrates on creating shareholder value and building transformative companies via early-stage, opportunistic, and diversified investments in the cannabis value chain in the U.S. and internationally. The Company’s partners include Aurora; Rthm Technologies, Inc.; Wagner Dimas; Body and Mind, Inc. (BaM); ShowGrow; Quality Green; Folium Biosciences; Mr. Natural, Inc.; and Green Therapeutics.

Recently, Australis Capital announced it entered into an asset purchase agreement with Green Therapeutics, LLC (GT) and affiliated companies, to acquire its Tsunami™, Provisions™, and GT Flowers cannabis brands, certain operating assets, intellectual property (IP), and the right to assume, complete and expand the construction of a state-of-the-art 55,000 square foot cultivation and production facility in North Las Vegas, Nevada. The 8.9-acre parcel of land in North Las Vegas has the potential to support a 400,000 square foot cultivation and production facility that will be built to the industry recognized Aurora Cannabis standard. This acquisition will include GT's experienced operating team.

In a separate transaction, Australis Capital acquired, from Meridian Companies LLC, an 8.9-acre parcel of land in North Las Vegas in exchange for $2 .93mm USD of its common stock or 3,585,521 Australis common shares where the new cultivation and production facility will be located.

Mr. Scott Dowty, Australis Capital’s Chief Executive Officer, said, "Green Therapeutics and Australis' combined assets, expertise, and network positions our company for tremendous growth and is uniquely positioned with products spanning verticals where long term margins will be insulated. Introducing Mr. Natural's Veteran Affairs registered premium organic strains and proprietary cultivation methodologies to Nevada through a purpose-built facility will serve as the launching ground for a nationally recognized cannabis brand."

Last week, Australis Capital announced it appointed Mr. Brent Reuter as its Senior Vice President, Investor Relations and Strategy. Mr. Reuter will concentrate on growth, partnership strategy, as well as investor relations. He comes to Australis Capital with considerable experience driving new revenue growth and managing businesses in the banking and investment sectors, most recently as Principal Investor Relations for Onex Corp, a private equity firm, Vice President of Asset Management for CIBC, and as Managing Director at RBC with roles in Hong Kong and New York.

Australis Capital, Inc. (AUSAF), closed Wednesday’s trading session at $0.7839, down 1.31%, on 82,570 volume with 54 trades. The average volume for the last 3 months is 190,791 and the stock's 52-week low/high is $0.40/$2.75.

chart

Grayscale Bitcoin Trust (GBTC)

CryptoCurrency Facts, Altcoin Buzz, InvestorsHub, Insider Financial, Zacks, Street Register, Bitcoinist, and Trading View reported previously on Grayscale Bitcoin Trust (GBTC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Grayscale Investments is the world’s largest digital currency asset manager. It is a global leader in digital currency asset management and its flagship asset is Grayscale Bitcoin Trust. Grayscale Investments provides opportunities for investors to gain exposure to digital currencies. The Company’s Grayscale Bitcoin Trust provides direct exposure to Bitcoin through a traditional investment vehicle. OTCQX-listed, Grayscale is headquartered in New York, New York.

Grayscale Investments is part of Digital Currency Group. The Company accesses the world’s largest network of industry intelligence to build better investment products. Grayscale has removed the barrier to entry so that institutions and individual investors can benefit from exposure to digital currencies. Astute investors can partake of the digital future with an institutional grade investment.

Grayscale Bitcoin Trust is the only publicly quoted U.S.-based Bitcoin investment product. In addition, it is the largest Bitcoin investment product worldwide. Grayscale Bitcoin Trust holds more than 1.2 percent of the outstanding Bitcoin supply (as of April 4, 2019).

Grayscale Investments announced in January 2019 that it launched Grayscale Stellar Lumens Trust. This is the first single-asset investment product that provides exposure to Lumens (XLM), the native asset of the Stellar network. This is the ninth single-asset investment product introduced by Grayscale Investments. The Company also manages Grayscale Digital Large Cap Fund™. This is a diversified investment product. It provides exposure to the top digital currencies by market capitalization.

Grayscale Investments introduced #DropGold on May 1, 2019. This is a campaign focused on the emergence of Bitcoin as an alternative to investing in gold. The campaign aims to shift the mindset around modern investment opportunities and portfolio allocations. #DropGold is about building awareness around Grayscale’s flagship Grayscale Bitcoin Trust (OTCQX: GBTC). However, it is also about promoting the emergence of Bitcoin as a viable digital asset.

Last month, Grayscale Investments announced that common units of fractional undivided beneficial interest (Shares) in Grayscale Ethereum Trust™ (ETHE) were approved by FINRA for a public quotation (Symbol: ETHE) on the OTC Markets. ETHE was launched in 2017 and is sponsored by Grayscale.

ETHE is an open-ended trust. It holds Ethereum and derives its value exclusively from the value of Ethereum. Investors in ETHE can gain exposure to the price movement of Ethereum without the challenges of buying, storing, and safekeeping Ethereum. As of April 30, 2019, each Share of ETHE represents ownership of 0.09662399 Ethereum. ETHE will not generate any income. It regularly distributes Ethereum to pay for its ongoing expenses. Consequently, the amount of Ethereum represented by each Share gradually decreases over time.

Grayscale Bitcoin Trust (GBTC), closed Wednesday’s trading session at $10.45, up 6.63%, on 4,497,152 volume with 6,837 trades. The average volume for the last 3 months is 4,529,151 and the stock's 52-week low/high is $3.66/$12.58.

chart

Humanigen, Inc. (HGEN)

NetworkNewsWire, TipRanks, Proactive Investors, Stockhouse, Marketbeat, StreetWise Reports, 4-Traders, Trading View, Investors Hangout, Whale Wisdom, Street Insider, GlobeNewswire, InvestorsHub, Insider Financial, Morningstar, Equity Clock, Barchart, Proactive Investors, and Stockopedia reported earlier on Humanigen, Inc. (HGEN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. is developing its Humaneered® proprietary monoclonal antibodies to address critical unmet needs in today's most advanced cancer therapies. A biopharmaceutical enterprise, the Company is developing its portfolio of Humaneered® monoclonal antibodies focused on CAR-T optimization and immuno-oncology. Humaneering is a patented proprietary technology for converting suboptimal antibodies into human antibodies suitable for chronic therapies, in part, because of low immunogenicity.

OTCQB-listed, Humanigen has its corporate office in Burlingame, California. The Company formerly went by the name KaloBios Pharmaceuticals, Inc. It changed its name to Humanigen, Inc. in August 2017.

Derived from Humanigen’s Humaneered® platform, lenzilumab and ifabotuzumab, and HGEN005 are monoclonal antibodies with first-in-class mechanisms. Lenzilumab targets GM-CSF. It is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, and also a potential treatment for hematologic cancers.

Ifabotuzumab targets the Eph type-A receptor 3 (EphA3). It is being explored as a potential treatment for glioblastoma multiforme (GBM) and a range of solid tumors, as an optimized naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.

HGEN005 selectively targets the eosinophil receptor EMR1. It is being explored as a potential treatment for a range of eosinophilic diseases including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct.

At the end of May, Kite, a Gilead Company (GILD) and Humanigen announced the creation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The aim of the study is to ascertain the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of the study and will be responsible for its conduct.

Cameron Durrant, MD, Chief Executive Officer of Humanigen, said, “Humanigen has pioneered the approach to neutralizing GM-CSF to improve CAR T. This collaboration with Kite will help validate the work Humanigen has done in understanding the pathophysiology of the inflammatory cascade as well as the potential role GM-CSF plays in influencing CAR T cell treatment outcomes.”

Humanigen, Inc. (HGEN), closed Wednesday’s trading session at $1.05, down 4.55%, on 13,277 volume with 11 trades. The average volume for the last 3 months is 6,846 and the stock's 52-week low/high is $0.27/$1.54.

chart

NaturalShrimp Incorporated (SHMP)

Micro Small Cap, Wall Street Analyzer, Stockwatch, Emerging Growth, OTC Markets, Transparent Traders, Market Screener, Live Trading News, and Stockhouse reported earlier on NaturalShrimp Incorporated (SHMP), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

An AquaCulture Company, NaturalShrimp Incorporated produces naturally-grown shrimp in the U.S. and internationally. The Company is a leader in the “Closed-System Shrimp Farming” industry. In 2016-17, it introduced its patented vibrio suppression technology that is potentially disruptive to the entire shrimp farming industry. OTCQB-listed, NaturalShrimp has its corporate headquarters in Addison, Texas. It has production facilities located near San Antonio, Texas.

NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp reliably and economically in an indoor, re-circulating, saltwater facility. The Company’s eco-friendly, bio-secure design does not rely on ocean water. It recreates the natural ocean environment allowing for high-density production that can be replicated anywhere in the world.

NaturalShrimp has completed final testing on its equipment. The Company is now beginning production. New equipment is coming in, and also saltwater and additional shrimp. NaturalShrimp Founder and Chief Executive Officer, Mr. Bill Williams, said this month, "When we get into full production, we will be raising 5,000-6,000 pounds of shrimp per week." The Company expects to reach full production by the end of this year.

The water systems used in production are electrified systems that help to control ammonia and bacteria, killing 99 percent of all bacteria. Shrimp are brought into the facility at 28 days old and are raised until maturity. This occurs around 14 weeks of age. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.

NaturalShrimp, utilizing its patented technology, continues to maintain the shrimp it stocked in July 2018, primarily to have fully grown shrimp for sampling to interested parties. The Company is now stocking shrimp on a monthly basis until required equipment is in place. It will subsequently stock two lots of shrimp per month until its current facility is full, expected to be by the end of this year. NaturalShrimp will then commence harvesting.

NaturalShrimp’s European partner has built a production facility in Medina del Campo, Spain. Expansion plans include domestic and international production facilities and distribution channels.

                   

NaturalShrimp Incorporated (SHMP), closed Wednesday’s trading session at $0.103, up 1.98%, on 1,487,528 volume with 167 trades. The average volume for the last 3 months is 4,235,023 and the stock's 52-week low/high is $0.005/$0.949.

chart

Rare Element Resources Ltd. (REEMF)

Investor Village, StreetWise Reports, BacktestMarket, Junior Mining Network, Zacks, Insider Financial, TipRanks, Investing.com, Real Investment Advice, Dividend Investor, Northern Miner, Marketbeat, and Stockhouse reported earlier on Rare Element Resources Ltd. (REEMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rare Element Resources Ltd. is a mineral resource company based in Littleton, Colorado. The Company is focusing on delivering strategic materials to technology industries by advancing plans to develop the Bear Lodge Critical Rare Earth Project in northeast Wyoming. It owns a 100 percent interest in a group of 499 unpatented mining claims and 640 acres owned in patent. The mine site is about 12 miles northwest of the town of Sundance, Wyoming. Rare Element Resources’ shares trade on the OTCQB.

Additionally, Rare Element Resources has an option on a parcel of land positioned on the outskirts of the town of Upton, Wyoming, around 40 miles to the southwest. This is the planned site for the Project's hydrometallurgical processing plant.

Extensive geological work by Rare Element Resources since 2004, including drilling, geophysical and geochemical sampling and assaying, has resulted in a Measured & Indicated resource of 18 million tons grading 3.05% Total Rare Earth Oxide (TREO) at a 1.5% cut-off grade for the Bear Lodge Project. This includes 3.0 million tons of Measured and 15 million tons of Indicated resource.

The Bear Lodge Project is located in one of the best mining districts in the world. The Project is rich in “critical rare earths” (CREE), those elements that are less common, higher valued and expected to experience better demand growth and price support over the long term.

Regarding Rare Earths at the Bear Lodge Project, the deposits there contain 10 rare earth elements. Of these, five are identified as "critical" in the Department of Energy, Critical Materials Strategy Report published in 2011. These five element plus praseodymiun, that the Company includes due to its ability to be substituted for Neodymiun in high intensity permanent magnets, are expected to account for greater than 80 percent of the Project's projected revenues.

In February 2019, Rare Element Resources announced major progress on the third-party test work relating to its proprietary rare earth separation technology being conducted by Umwelt-und Ingenieurtechnik GmbH Dresden (UIT). UIT is an affiliate of Synchron, a significant shareholder of the Company. Rare Element Resources engaged UIT in April of 2018 to validate and further enhance its proprietary rare earth element processing technology.

UIT has advanced mineral and materials research capabilities in Dresden, Germany. UIT reported that its test work successfully validated Rare Element Resources’ proprietary technology and process flowsheet and identified additional opportunities for improvement.

Rare Element Resources Ltd. (REEMF), closed Wednesday’s trading session at $0.44, down 10.20%, on 295,407 volume with 109 trades. The average volume for the last 3 months is 346,643 and the stock's 52-week low/high is $0.03/$0.60.

chart

Thunder Energies Corporation (TNRG)

Wallet Investor, Morningstar, YCharts, The Street, Stockwatch, Market Exclusive, Investor Place, The Silicon Review, InvestorsHub, Emerging Growth, Penny Stock Tweets, Penny Stock Hub, ResearchPool, Capital Cube, The Stock Radio, and Marketbeat reported previously on Thunder Energies Corporation (TNRG), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Thunder Energies Corporation concentrates on the manufacture, sale, and service of diverse technologies in the U.S. The Company previously went by the name Thunder Fusion Corporation. In May 2014, it changed its corporate name to Thunder Energies Corporation. Listed on the OTC Markets, Thunder Energies is based in Tarpon Springs, Florida.

The Company markets its technologies via three divisions. These are Optical Instruments, Combustion Equipment, and Nuclear Instruments. Concerning the Division of Optical Equipment, its emphasis is the production, promotion, sale and service of pairs of Galileo telescopes with convex lenses to detect matter-galaxies & Santilli telescopes with concave lenses to detect antimatter-galaxies (international patent pending).

Regarding the Division of Combustion Equipment, its focus is the production, promotion, sale and service of the novel HyperFurnace that attains the total combustion of fossil fuels and an enhanced energy output (patented and international patents pending).

Pertaining to the Division of Nuclear Equipment, the production, promotion, sale and service of the Santilli Thermal Neutron Source is based on a novel synthesis of the neutron from a hydrogen gas (international patent pending).

Thunder Energies’ Division of Combustion is successfully continuing the development of the new chemical species of gas named MagneHydrogen. The Company has secured the required domain names, has applied for available trademark protections and is finalizing engineering schematics for the first production of MagneHydrogen, separated from commercially available MagneGas through standard Pressure Swing Absorption equipment.

Recently, Thunder Energies announced the initiation of the construction of a prototype Precious Metal Detector. Funding is from the S1 registration on record with GHS Investments in New York. Dr. Ruggero M. Santilli, Thunder Energies’ Chief Executive Officer, stated, "I am pleased to announce that, thanks to the availability of funds, our Company has initiated works necessary for the construction of a prototype Precious Metal Detector based on our Directional Neutron Source…”

Thunder Energies also recently announced the initiation of construction of its Precious Metal Detector in conformity with the recent upgrade of the Letter of Intent (LOI) for its test and use.

Dr. Ruggero M. Santilli stated, "I am pleased to report the initiation of construction of the prototype Thunder Energies Precious Metal Detector following completion of all background research… We are currently completing the design of the Directional Neutron Source needed in mining operations and look forward with great confidence to the successful completion of the project."

Thunder Energies Corporation (TNRG), closed Wednesday’s trading session at $0.002, up 11.11%, on 120,000 volume with 4 trades. The average volume for the last 3 months is 1,424,846 and the stock's 52-week low/high is $0.0018/$0.0318.

chart

Sun BioPharma, Inc. (SNBP)

Ahead of the Bulls, All Penny Stocks, The Stock Wizards, The Dean, FeedBlitz, Microcap Voice, Hot Shot Stocks, Wall Street Resources, Lebed, Today's Financial News, Hot Penny Stocks Now, OTC Picks, Beacon Equity Research, Greenbackers, CoolPennyStocks, Otcstockexchange, and HotOTC reported previously on Sun BioPharma, Inc. (SNBP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Sun BioPharma, Inc. is a Biopharmaceutical Company listed on the OTCQB. It is developing disruptive therapeutics for the treatment of patients with pancreatic diseases.  A clinical-stage biopharmaceutical enterprise, Sun BioPharma’s development programs target diseases of the pancreas. This includes pancreatic cancer and pancreatitis. Sun BioPharma has its corporate office in Waconia, Minnesota.

The Company has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, California; the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia, and the Ashford Cancer Centre in Adelaide, Australia.

Sun BioPharma’s first product candidate is SBP-101. This product is for the treatment of patients with pancreatic cancer.  Mr. Ray Bergeron, Ph.D. Distinguished Professor Emeritus, University of Florida invented SBP-101.The Company’s plan is to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, the most common kind of pancreatic cancer.

SBP-101 is a first-in-class, proprietary, polyamine compound. The design of it is to exert therapeutic effects in a mechanism specific to the pancreas. In 2011, Sun BioPharma originally licensed SBP-101 from the University of Florida.

The Company’s SBP-102 is currently in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. In addition, its SBP-103 is currently in non-clinical exploratory evaluation.

On November 1, 2018, Sun BioPharma presented results of a new study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” at the American Pancreatic Association meeting in Miami, Florida that day. The study, performed in collaboration with Cedars-Sinai Medical Center in Los Angeles, California and funded by the National Institutes of Health, evaluated the ability of SBP-101, a polyamine metabolic inhibitor (PMI), to impact the development of acute pancreatitis using different formulations and dosing regimens.

Michael Walker, MD, Director of Pancreatic Research at Sun BioPharma and one of the study’s co-Principal Investigators, said then “In some instances, administration of SBP-101 was able to decrease levels of amylase and lipase, markers of acute pancreatitis in the blood, and reduce swelling and inflammation in the pancreas.”

Sun BioPharma, Inc. (SNBP), closed Wednesday’s trading session at $2.45, up 8.89%, on 1,000 volume with 2 trades. The average volume for the last 3 months is 742 and the stock's 52-week low/high is $2.00/$6.75.

chart

Artelo Biosciences, Inc. (ARTL)

NetworkNewsWire, Stockwatch, MarketWatch, Simply Wall St, OTC Markets, Stockopedia, The Street, Dividend Investor, Digital Journal, Trading View, Biospace, GuruFocus, Stockhouse, Wallmine, Simply Wall St, Market Screener, Real Investment Advice, last10k, Market Exclusive, Venture Line, and InvestorsHub reported earlier on Artelo Biosciences, Inc. (ARTL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company centered on the development of therapeutic treatments that modulate the endocannabinoid system. It is advancing a portfolio of widely applicable product candidates. The design of these is to address significant unmet needs in manifold diseases and conditions, including cancer, pain, and inflammation. Artelo Biosciences has its head office in La Jolla, California.

The endocannabinoid system (ECS) is a widespread neuromodulatory system. It plays a vital role in human central nervous system development, synaptic plasticity, and the response to endogenous and environmental insults.

Artelo Biosciences’ approach exploits numerous mechanisms to modulate the ECS. Candidate therapeutic compounds in its current portfolio are based on targeting cannabinoid receptors and endocannabinoid transport inhibition using synthetic cannabinoids and new chemical entity approaches.

Artelo’s emphasis is on providing patient access to new therapies and applying proven biopharma thoroughness to its development programs. Furthermore, it is driving innovative endocannabinoid system modulating therapeutics into new areas. The Company is also partnering with world-class experts.

Artelo Biosciences earlier entered into a global research and development (R&D) partnership with Syngene International Ltd., an India-based integrated discovery-development service provider, through its wholly-owned subsidiary, Trinity Research and Development Limited, and Aptus Clinical Ltd., a specialist UK-based Clinical Contract Research Organization (CRO) with specific expertise in oncology, rare diseases and advanced therapies. The partnership centers on supporting the drug discovery and clinical development of ART27.13, Artelo Biosciences’ Phase 2 ready, high-potency dual cannabinoid agonist, in oncology.

Recently, Artelo Biosciences announced positive preclinical results with its product candidate, ART27.13, a clinic-ready, potent, peripherally restricted CB1/CB2 synthetic agonist with a target indication in cancer-related anorexia and weight loss. Of note, ART27.13 demonstrated in-vitro anti-proliferative activity in cancer cell line cultures.

The results are alike to activity shown by other cannabinoid compounds. The Company says they are encouraging to the continued evaluation of ART27.13 as a potential anti-cancer agent, in addition to its expected role in treating anorexia. Artelo Biosciences is continuing clinical study-enabling activities for ART27.13 for a Phase 1b/2a study in cancer-related anorexia planned to begin this year.

Artelo Biosciences, Inc. (ARTL), closed Wednesday’s trading session at $1.00, up 1.01%, on 5,600 volume with 10 trades. The average volume for the last 3 months is 1,289 and the stock's 52-week low/high is $0.27/$1.75.

chart

Delcath Systems, Inc. (DCTH)

OTC Markets, InvestorsHub, Proactive Investors, SuperStockScreener, Stocks Gallery, 4-Traders, Barchart, Invest.com, Morningstar, Stock News Journal, Stocktwits, Trading View, MarketWatch, Stockhouse and Insider Financial reported earlier on Delcath Systems, Inc. (DCTH),  and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Its investigational product is Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The design of this product is to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Delcath Systems is based in New York, New York. The Company’s shares trade on the OTCQB.

Delcath Systems has supported clinical research of liver directed high dose chemotherapy in patients with metastatic ocular and cutaneous melanoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and hepatocellular carcinoma.  Liver directed high dose chemotherapy uses percutaneous hepatic perfusion (PHP) to deliver concentrated doses of a chemotherapeutic agent directly to the liver.

The Company’s system has been commercially available in Europe since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In Europe, it has been used at major medical centers to treat a broad array of cancers of the liver. Delcath is working on advancing its clinical programs of its unique Melphalan/HDS.

Melphalan/HDS has not been approved by the U.S. Food & Drug Administration  (FDA) for sale in the United States.  Additionally, Delcath is working to increase commercialization efforts for CHEMOSAT in Europe. The Company continues its focus on the clinical trials, which comprise the Clinical Development Program (CDP).

Delcath Systems has begun a worldwide Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM). It plans to start a global registration trial for intrahepatic cholangiocarcinoma (ICC).

Recently, Delcath Systems announced that it received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. This approval of CHEMOSAT as a Class 3 medical device was issued by the Agência Nacional de Vigilância Sanitária (ANVISA). It permits the marketing and utilization of CHEMOSAT under the same percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood indication, as in Europe.

Delcath Systems, Inc. (DCTH), closed Wednesday’s trading session at $0.1032, up 3.20%, on 78,994 volume with 36 trades. The average volume for the last 3 months is 338,065 and the stock's 52-week low/high is $0.067/$10.30.

chart

Rocky Mountain High Brands, Inc. (RMHB)

Penny Picks, SizzlingStockPicks, WallstreetSurfers, ProTrader, Fortune Stock Alerts, SmallCapVoice, Promotion Stock Secrets, PennyPickAlerts, Damn Good Penny Picks, and Winston Small Cap reported previously on Rocky Mountain High Brands, Inc. (RMHB), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Rocky Mountain High Brands, Inc. is a consumer goods business listed on the OTC Markets’ OTCQB. The Company’s specialty is brand development of health conscious, hemp-infused, food and beverage products and naturally high alkaline water. Rocky Mountain High Brands has launched its naturally high alkaline spring water, Eagle Spirit Spring Water. The Company is based in Dallas, Texas.

Rocky Mountain High Brands has acquired all of the assets, trademarks, intellectual property (IP) and ongoing business operations of BFIT Brands, LLC of Phoenix, Arizona. BFIT Brands sells the whey protein and energy drink, FitWhey.

Rocky Mountain High Brands currently markets a lineup of two naturally flavored hemp-infused functional beverages under the name Rocky Mountain High. Regarding its Eagle Spirit Spring Water, it is a naturally high alkaline spring water from a secluded spring at the foot of the ancestral Rocky Mountains.

Rocky Mountain High Brands has launched its HEMPd Infusion Flavored Waters on its www.HEMPd.com website. It has four flavors of HEMPd Infusion Flavored Waters. These are Raspberry Lemonade, Peach Mango, Dragon Fruit, and Pineapple Coconut and each contains 5 mg of full plant cannabidiol (CBD).

Rocky Mountain High Brands has been granted permission to be the sole provider of high-quality drinks containing CBD to sell throughout Mexico by RCH Grupo’s subsidiary, CBD Life. It is the first time a U.S. company has manufactured a hemp product in the form of beverages for sale in Mexico.

Recently, Rocky Mountain High Brands announced an update on its agreement with CBD Life, a subsidiary of RCH Grupo. On December 28, 2018, the Company received the initial purchase order and deposit from CBD Life for an initial test run of 2,000,000 cans of Rocket High, California Lemonade and California Black Tea.

Also recently, representatives of CBD Life met with Rocky Mountain High Brands Officers at their Corporate Headquarters in Dallas. The purpose of the meeting was for the representatives to gain an understanding of Rocky Mountain High’s status on the initial purchase order for CBD Life and to set expectations for purchase orders to follow throughout the rest of 2019.

Rocky Mountain High Brands, Inc. (RMHB), closed Wednesday’s trading session at $0.0523, up 0.58%, on 306,851 volume with 54 trades. The average volume for the last 3 months is 5,355,953 and the stock's 52-week low/high is $0.0445/$0.33.

chart

Planet 13 Holdings, Inc. (PLNHF)

MicroCap Daily, Wallet Investor, Pot Network, Penny Stock Hub, Markets and Research, InvestorX, MicroSmallCap, Market Screener, Stockhouse, MarketWatch, Dividend Investor, Trading View, Morningstar, Financial Content, and InvestorsHub reported earlier on Planet 13 Holdings, Inc. (PLNHF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Planet 13 Holdings, Inc. is a vertically integrated cannabis company listed on the OTCQB. It has award-winning cultivation, production, and dispensary operations in Las Vegas, Nevada. The Company is an established cannabis leader in the Nevada market. Its emphasis is on providing a premier dispensary experience and optimizing cultivation efficiencies via its best-in-class technology, as the frontline of cannabis. Planet 13 Holdings is headquartered in Las Vegas.

The Company’s mission is to build a recognizable worldwide brand known for first-rate dispensary operations, and a creator of unique cannabis products. On November 1, 2018, Planet 13 opened the largest, most advanced retail dispensary in the world immediately next to the Las Vegas strip. The new facility features 16,200 sq. ft. of dispensary space.

Planet 13 has 6-plus Cannabis Licenses. It is fully licensed for cultivation, retail distribution and more in the fast developing Nevada market. The Company’s Medizin dispensaries provide top quality recreational cannabis, cannabis extracts, and infused products. Medizin also centers on industry-leading customer experiences. It produces flower, concentrates, vape pens, edibles and more. Medizin (Medical) and Planet 13 (Recreational) brands are already some of the most awarded cannabis product brands in Nevada.

Planet 13 announced in November of 2018 that it launched its second wholly-owned brand, TRENDI. TRENDI represents expertly crafted disposable vape and concentrate products. Fundamentally, they create the trend, not the other way around. TRENDI employs state-of-the-art hydro carbon extraction technology further refined by fractional distillation. It delivers a very high potency product. The TRENDI line of products will be exclusive to the Planet 13 Superstore. TRENDI will be powered by a curated array of strains, processed into ultra-premium disposable vapes and concentrates at Planet 13’s production facilities.

Recently, Planet 13 announced that in January it served an average of 1,550 customers per day at its Superstore in Las Vegas versus 1,430 customers per day in December. This represents a month-over-month increase of 8.4 percent. In addition, Planet 13 stated that its average ticket size for the month was higher than expected.

Also recently, Planet 13 commended the proposal by Governor Sisolak to establish the Cannabis Compliance Board (CCB) that will review recent licensing procedures. This includes the most recent licensing round announced on December 5, 2018. Moreover, the CCB will oversee the development of future legislation including that governing consumption lounges.

Planet 13 Holdings, Inc. (PLNHF), closed Wednesday’s trading session at $2.10, down 0.52%, on 136,628 volume with 262 trades. The average volume for the last 3 months is 330,037 and the stock's 52-week low/high is $0.501/$2.70.

chart

Medifocus, Inc. (MDFZF)

MoneyHub, OTC Markets, Wallet Investor, SmallCapVoice, Investor Place, Investor Network, Barchart, Street Insider, Financial Content, Trading View, MarketWatch, and otc.Watch reported beforehand on Medifocus, Inc. (MDFZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medifocus, Inc. has a portfolio of medical technologies that use patented  Focal Thermal Technology  to treat conditions ranging from Prostate Diseases to Breast Cancer. The Company’s portfolio of medical products includes thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer. OTCQB-listed, Medifocus is based in Columbia, Maryland.

The Company owns two technology platforms with approximately 100 issued and pending U.S. and worldwide patents. One platform is the “Endo-thermotherapy Platform”. The other platform is the “Adaptive Phased Array Microwave Focusing Platform”.

Based on these proprietary technology platforms, Medifocus has developed two advanced therapeutic products. One is the Prolieve® system for the treatment of BPH. The other is the Adaptive Phased Array (APA)-1000 system for the treatment of breast cancer.

The Prolieve® Thermodilatation™ System provides symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) via a simple, 45-minute, in-office treatment. Prolieve® is Food and Drug Administration (FDA) and Medicare approved for treating symptomatic BPH with more than 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy, and durability. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy, and also certain types of surgical procedures to treat the symptoms of BPH.

Medifocus’ Heat Activated Gene Therapy, exclusively licensed from Duke University, aims at using the Company’s Focal Thermal Technology to enhance selective expression of therapeutic genes injected intratumorally to optimize cancer cell killing while lessening systemic side effects.

The APA 1000 Breast Cancer Treatment System developed by the Massachusetts Institute of Technology (MIT) has been shown in Phase 2 clinical trials to offer substantial additional shrinkage of the sizes of breast cancer in combined ChemoThermal therapy versus Chemotherapy alone. Additionally, it was shown to be effective in reducing margin positivity when patients were treated with APA 1000 before lumpectomy.

Recently, Medifocus announced that its Prolieve® Thermodilatation™ procedure for the treatment of BPH have been performed and reimbursed by insurance carriers in Hong Kong.

Dr. William Jow, said, “We are pleased that our efforts, together with the contribution from our Asian partners, are starting to yield tangible financial results from Prolieve® sales. Through our resolution in promoting Prolieve® in Asia and after having presented at three major international conferences within the past 16 months, I would like to see Prolieve® sales start to pick up in the near future both domestically and internationally. We are pleased to enter the fast-growing Asia markets where BPH and cancers of the prostate and breast are quickly becoming major public health concerns.”

Medifocus, Inc. (MDFZF), closed Wednesday’s trading session at $0.01426, up 8.85%, on 39,709 volume with 1 trade. The average volume for the last 3 months is 3,015 and the stock's 52-week low/high is $0.006/$0.031.

chart

The QualityStocks Company Corner

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) was featured today in the 420 with CNW by CannabisNewsWire. According to a new policy which has just been made public by Transport Canada (the federal transport regulator), flight crews as well as other industry employees will no longer be allowed to use marijuana within 28 days before they are due to fly. The policy, which was announced on Thursday (June 6), takes immediate effect and it affects cabin crew, pilots and air traffic controllers. This policy was released in order to clarify the position of the regulator when recreational marijuana was legalized on October 17 last year.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $3.87, up 4.59%, on 288,136 volume with 774 trades. The average volume for the last 3 months is 443,139 and the stock's 52-week low/high is $2.40/$11.82.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was recently featured in an article on Cannabis News Update titled '5 CBD Vape Pens We Love At CNU' authored by Adrian Daniel. Featured alongside other brands including Select CBD Focus Vape Pen and Pure Spectrum’s CBD Honey Oil, Wildflower stands out with its sleek and appealing mint green CBD Immunity Vaporizer. This disposable vaporizer includes more than just CBD oil. Consumers can also enjoy the benefits of eucalyptus, cinnamon, and myrrh to boost their immune system. Wildflower’s CBD Immunity Vaporizer is available for purchase on the company’s website at http://nnw.fm/rXA7w. To view the full article, visit: http://nnw.fm/78tST.

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was recently featured in an article on Cannabis News Update titled '5 CBD Vape Pens We Love At CNU' authored by Adrian Daniel. Featured alongside other brands including Select CBD Focus Vape Pen and Pure Spectrum’s CBD Honey Oil, Wildflower stands out with its sleek and appealing mint green CBD Immunity Vaporizer. This disposable vaporizer includes more than just CBD oil. Consumers can also enjoy the benefits of eucalyptus, cinnamon, and myrrh to boost their immune system. Wildflower’s CBD Immunity Vaporizer is available for purchase on the company’s website at http://nnw.fm/rXA7w. To view the full article, visit: http://nnw.fm/78tST.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.4905, up 3.72%, on 13,765 volume with 11 trades. The average volume for the last 3 months is 24,210 and the stock's 52-week low/high is $0.009/$1.129.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST) operates in the hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development fields. A biotechnology company headquartered in Doral, Florida, ETST markets high purity and quality full-spectrum cannabinoids. The company’s wholly owned subsidiaries – including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and Canna Inno Laboratories Inc. – concentrate on developing Earth Science Tech’s role as a worldwide leader in the CBD sector.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.74, up 27.59%, on 271,223 volume with 99 trades. The average volume for the last 3 months is 36,428 and the stock's 52-week low/high is $0.300/$2.45.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) on Tuesday announced the voting results from its annual general meeting (“AGM”) of shareholders of the company, which was held in Mississauga, Ontario on June 11, 2019. According to the update, all matters put before shareholders for consideration were approved by the majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, as well as items of business including setting of the company’s number of directors at six; and the appointment of KPMG LLP as the company’s auditor for the ensuing year and authorization of directors to fix their remuneration. To view the full press releases, visit: http://nnw.fm/N2ZlB and http://nnw.fm/WcTJ9.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.57, up 0.39%, on 423,961 volume with 638 trades. The average volume for the last 3 months is 952,803 and the stock's 52-week low/high is $1.6069/$7.894.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions Inc. (OTCQB: SGSI) says that its bundling of services and the low number of qualified services firms in the growing telecommunications market helped drive higher revenues and growth in its margin potential on projects in the first quarter of 2019 (http://nnw.fm/bCk1m).

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.145, up 7.41%, on 25,250 volume with 5 trades. The average volume for the last 3 months is 52,072 and the stock's 52-week low/high is $0.071/$2.59.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Nabis Holdings (CSE:NAB) (OTC: INNPF) (FRA: 71P), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, this morning announced its entry into a definitive agreement to acquire 100% ownership of Desert’s Finest, a Desert Hot Springs, California-based 6,000 square foot dispensary. To view the full press release, visit: http://nnw.fm/ZT28p.

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.306, off by 21.30%, on 67,290 volume with 49 trades. The average volume for the last 3 months is 184,895 and the stock's 52-week low/high is $0.306/$0.791.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. To view the full publication, titled “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments,” please visit: http://cnw.fm/O5Oes.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.86995, off by 3.47%, on 21,767 volume with 35 trades. The average volume for the last 3 months is 105,067 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled “Swelling Battery Demand Keeps Indonesian Nickel Sector Strong,” visit: http://nnw.fm/y5aT6.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed the day's trading session at $0.110038, off by 4.23%, on 775 volume with 2 trades. The average volume for the last 3 months is 23,957 and the stock's 52-week low/high is $0.07/$0.378.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood, Inc. (OTCQB: NGTF), the innovative ice cream company solving America’s $50 billion-dollar nighttime snacking problem, today announced it has partnered with leading parenting community Moms Meet to support the Nightfood national supermarket roll-out.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.385, off by 2.51%, on 82,694 volume with 42 trades. The average volume for the last 3 months is 326,594 and the stock's 52-week low/high is $0.16/$0.92.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-base instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that the Company's patented pressure cycling technology ("PCT") platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry ("ASMS"), held from June 1-6, 2019 in Atlanta, GA.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $2.79, off by 3.12%, on 1,950 volume with 9 trades. The average volume for the last 3 months is 8,760 and the stock's 52-week low/high is $1.52/$4.10.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD), a leading provider of hydroponic and other supplies to the agricultural and hemp sectors, today announces a new business initiative, which is expected the expand the Company's revenue base. Over the coming weeks, the Company will be entering the market for hemp extraction equipment and technologies, including several Chinese proprietary technologies, which hold the promise of increasing extraction efficiencies. Also today, CannabisNewsWire released a report on the company detailing how, in the modern market, CBD is a kind of raw currency, a sure seller that can be easily turned into cash by companies with even halfway capable supply chains and marketing. Additionally, the company was highlighted in a publication from Financialnewsmedia.com, examining how recent articles abound in the reverberations of the public’s ever-increasing demand for CBD infused products. To view the full publication, titled “Demand for CBD Places Power in Hands of Extraction Providers,” please visit: http://cnw.fm/3TxSW.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.0405, off by 5.81%, on 2,143,340 volume with 217 trades. The average volume for the last 3 months is 1,641,304 and the stock's 52-week low/high is $0.0225/$0.1975.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) ("GGB" or "the Company") today announced that it has surpassed 50 Seventh Sense Botanical Therapy ("Seventh Sense") shops open in four months. The first Seventh Sense shop opening was announced mid-February, and, since that time, GGB has continued to roll out its Seventh Sense shops at a rapid pace. The Company anticipates opening more than 200 such shops by the end of 2019.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $2.39, off by 3.95%, on 248,947 volume with 401 trades. The average volume for the last 3 months is 259,127 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: ZRRRF).

National cannabis holding company IONIC Brands (CSE: IONC) (OTC: ZRRRF), formerly Zara Resources Inc., this morning announced the completion of the acquisition of Vegas Valley Growers North (“VVG”). To view the full press release, visit: http://nnw.fm/55BFq.

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC's product lines are pioneering the changing landscape of cannabis consumption. The company's refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC's Certified Clean program verifies that every product leaving the company's facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green's technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package's QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company's flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC's immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC's expansion and development into Washington state's leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck's.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC's aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the "Top 50 Companies to Work for in Cannabis" by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: ZRRRF), closed the day's trading session at $0.30, off by 8.93%, on 163,969 volume with 88 trades. The average volume for the last 3 months is 290,079 and the stock's 52-week low/high is $0.036/$0.6346.

Recent News

chart

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF).

Chemistree Technology Inc. (CSE:CHM) (OTCQB:CHMJF) was highlighted today in a publication by Pot Stock News, examining how America’s cannabis market continues to expand. with 33 medical marijuana-legal states, 10 states with legalized adult consumption, and 4 states on the path to becoming the next to legalize recreational marijuana: Illinois, Ohio, New York, and New Jersey. In turn, cannabis companies are taking strategic steps to ensure their international expansion plans include making inroads into the world’s largest economy.

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF), an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements' expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company.

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company "maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S."

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree's working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed the day's trading session at $0.31, off by 5.78%, on 86,837 volume with 63 trades. The average volume for the last 3 months is 104,717 and the stock's 52-week low/high is $0.268/$0.605.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.